Table 2.
Most common concomitant medications including expected drug-drug interactions with antiviral therapy*
| Concomitant medication | Number of patients (%) | Expected interactions** |
|---|---|---|
| Pantoprazole | 17 (8.1) | Potential weak interaction |
| Furosemide | 15 (7.2) | Potential interaction |
| Spironolactone | 14 (6.7) | No interaction expected |
| Ursodeoxycholic acid | 14 (6.7) | No interaction expected |
| Mycophenolate | 11 (5.3) | Potential interaction |
| Tacrolimus | 11 (5.3) | Potential interaction |
| Insulin | 10 (4.8) | No interaction expected |
| Levothyroxine | 10 (4.8) | Potential interaction |
| Acetylsalicylic acid (aspirin) | 9 (4.3) | No interaction expected |
| Bisoprolol | 8 (3.8) | Potential interaction |
| Prednisone | 8 (3.8) | Potential interaction |
| Propranolol | 8 (3.8) | No interaction expected |
| Prednisolone | 7 (3.3) | No data |
| Alfacalcidol | 6 (2.9) | No data |
| Amlodipine | 6 (2.9) | Potential interaction |
| Omeprazole | 6 (2.9) | Potential weak interaction |
| Torasemide | 6 (2.9) | No interaction expected |
| Calcium | 6 (2.9) | No data |
| Vitamin K (phytonadione) | 6 (2.9) | No data |
| Carvedilol | 5 (2.4) | Potential interaction |
| Magnesium | 5 (2.4) | Potential interaction |
| Metformin | 5 (2.4) | No interaction expected |
| Ornithine aspartate | 4 (1.9) | No data |
| Azathioprine | 4 (1.9) | No interaction expected |
| Indapamide | 4 (1.9) | Potential interaction |
| Metoprolol | 4 (1.9) | No interaction expected |
| Ramipril | 4 (1.9) | No interaction expected |
| Potassium | 4 (1.9) | No interaction expected |
| Ranitidine | 4 (1.9) | No interaction expected |
| Valsartan | 4 (1.9) | Potential interaction |
| Cyclosporine | 3 (1.4) | Potential interaction |
| Nebivolol | 3 (1.4) | No interaction expected |
| Losartan | 3 (1.4) | No interaction expected |
| Hydrochlorothiazide | 3 (1.4) | No interaction expected |
| Gliclazide | 3 (1.4) | Potential interaction |
| Betahistine | 3 (1.4) | No data |
| Allopurinol | 3 (1.4) | No interaction expected |
*
The analysis did not include ribavirin.
**
Based on data from the online drug interaction tool (http://www.hep-druginteractions.org/)